Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Bayer HealthCare Animal Health
Operations will remain in St. Joseph, MO and Bayer will invest an estimated $10 million to manage vital U.S. product supply operations
SHAWNEE, Kan., Jan. 20, 2014 /PRNewswire/ -- Bayer HealthCare LLC announced today that the company will be improving efficiency and investing in its manufacturing operations in Missouri. The company will combine and transfer operations from three locations in the St. Joseph area to one beginning this year. Additionally, Bayer will be transferring its regulatory and development activity to its U.S. headquarters based in Shawnee, Kan. by early 2015. The company will invest an estimated $10 million dollars between its Kansas and Missouri sites located in the greater Kansas City region, which is part of the Animal Health Corridor.
"One year post-acquisition, this is the next logical step in the integration process," said Steve Meeker, vice president, Product Supply, U.S. Animal Health. "The employees of the St. Joseph Product Supply Manufacturing site have done an excellent job in delivering quality products on a timely basis for support of our commercial requirements. We have completed the analysis of the business and identified overlaps in technology and operating processes with the Shawnee Supply Center that, once optimized, will provide Bayer with a sustainable, cost-competitive, long-term manufacturing operation. The St. Joseph Supply Center will continue to be an important part of Bayer's supply strategy and, as such, we have decided to invest an estimated $6.5 million in upgrades to our St. Joseph campus."
Bayer acquired the St. Joseph facilities in January 2013 following its acquisition of the U.S.-based animal health business of Teva Pharmaceutical Industries that strengthened the company's food animal business with a range of anti-infectives, anti-inflammatories and reproductive hormones. It also enabled Bayer to build its companion animal veterinary business by expanding its portfolio with dermatological, pet wellness and nutraceutical products.
"Bayer's U.S. Animal Health business is vital to the overall attainment of the company's global animal health success," said John Koelink, head of Product Supply, Animal Health. "This strategic decision to optimize operations will ensure the long-term vitality of the business and our U.S. operations, including both the St. Joseph and Shawnee facilities."
Bayer will also invest an estimated $3.5 million in its Shawnee site to consolidate and build R&D capabilities. The overall manufacturing operations optimization is expected to be completed early next year. These changes may result in some personnel changes over the next one to two years; however, it is too soon to determine the individual impact, according to Meeker.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 54,900 employees (Dec. 31, 2012) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.
Staci Gouveia, Tel. 203.809.9008
Lauren Dorsch, Tel. 913.827.6306
Find more information about Bayer HealthCare Animal Health at
Follow us on Twitter: @Bayer4animalsUS
Follow us on Facebook: https://www.facebook.com/healthcare.bayer
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
©2012 PR Newswire. All Rights Reserved.